TITLE

Augmentation therapy for severe α1-antitrypsin deficiency: is the jury still out on a trial?

AUTHOR(S)
Stoller, James K.
PUB. DATE
December 1998
SOURCE
Thorax;Dec1998, Vol. 53 Issue 12, p1007
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
67206343

 

Related Articles

  • Alpha1-Antitrypsin Deficiency. G�tzsche, Peter C.; Johansen, Helle K. // New England Journal of Medicine;11/19/2009, Vol. 361 Issue 21, p2101 

    A letter to the editor is presented in response to an article on two small trials of augmentation therapy for alpha-antitrypsin deficiency by E. K. Silverman and colleagues in the June 25, 2010 issue.

  • Alpha1-Antitrypsin Deficiency. Taylor, Nicholas J.; Shawcross, Debbie L. // New England Journal of Medicine;11/19/2009, Vol. 361 Issue 21, p2101 

    A letter to the editor is presented in response to an article on two small trials of augmentation therapy for alpha-antitrypsin deficiency by E. K. Silverman and colleagues in the June 25, 2010 issue.

  • Alpha1-Antitrypsin Deficiency. Silverman, Edwin K.; Sandhaus, Robert A. // New England Journal of Medicine;11/19/2009, Vol. 361 Issue 21, p2101 

    A response by Edwin K. Silverman and Robert A. Sandhaus to a letter to the editor about their article on two small trials of augmentation therapy for alpha-antitrypsin deficiency in the June 25, 2010 issue is presented.

  • Augmentation Therapy Reduces Lung Density Loss in Alpha-1.  // AARC Times;Aug2013, Vol. 37 Issue 8, p60 

    The article reports that the clinical trial of alpha-1 proteinase inhibitor (A1-P1) augmentation therapy among alpha-1 antitrypsin deficiency (AATD) patients shows that the treatment is effective.

  • α1 - Antitrypsin deficiency 5: Intravenous augmentation therapy: current understanding. Stoller, J. K.; Aboussouan, L. S. // Thorax;Aug2004, Vol. 59 Issue 8, p708 

    The biochemical and clinical efficacy of intravenous augmentation therapy in α1 -antitrypsin deficiency is reviewed, adverse events experienced with this treatment are considered, and its cost effectiveness is discussed.

  • Pulmonary Disease in Alpha-1-Antitrypsin Deficiency. Snider, Gordon // Annals of Internal Medicine;12/15/89, Vol. 111 Issue 12, p957 

    Editorial. Comments on the association of alpha-1-antitrypsin (AAT) deficiency with the development of pulmonary disease in early or mid-life. Reason for the occurrence of pulmonary emphysema; Components of AAT; Effecfiveness of augmentation therapy in the treatment of patient with AAT deficiency.

  • High dose intravenous AAT and plasma neutrophil derived fibrinogen fragments. Stolk, J.; Nieuwenbuizen, W. // Thorax;Jan2005, Vol. 60 Issue 1, p84 

    Presents a letter to the editor on high dose intravenous therapy for antitrypsin deficiency.

  • α-Antitrypsin: Hope on the Horizon for Emphysema Sufferers? Schwaiblmair, M.; Vogelmeier, C. // Drugs & Aging;1998, Vol. 12 Issue 6, p429 

    α-Antitrypsin (αAT) deficiency is the most common genetic cause of liver disease in children and emphysema in adults. Therapy for pulmonary disease attributable to αAT deficiency includes αAT augmentation therapy along with supportive measures. The αAT preparation that is...

  • Augmentation Therapy for α1-Antitrypsin Deficiency. Juvelekian, Georges S.; Stoller, James K. // Drugs;2004, Vol. 64 Issue 16, p1743 

    α1-Antitrypsin (AAT) deficiency is a common but under-recognised condition. Since its first description by Laurell and Eriksson in 1963, significant advances have been made in understanding the genetics, physiology and pathophysiology of this condition. The intravenous administration of...

  • Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema. Blanco, Ignacio; Lara, Beatriz; de Serres, Frederick // Orphanet Journal of Rare Diseases;2011, Vol. 6 Issue 1, p14 

    Up to now alpha 1-antitrypsin (AAT) augmentation therapy has been approved only for commercial use in selected adults with severe AAT deficiency-related pulmonary emphysema (i.e. PI*ZZ genotypes as well as combinations of Z, rare and null alleles expressing AAT serum concentrations <11...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics